Alymsys Injection, Solution
Product Images NDC 70121-1755

This appears to be a clinical trial progress chart showing the number of patients and time in months. Two different treatment groups (IFL + Placebo and IFL + Bevacizumab) are being compared. However, without more context or information, it is not possible to draw any further conclusions from this text.*

This is a description of Alymsys, a medication manufactured by Amneal Pharmaceuticals LLC in Bridgewater, NJ, USA. The medication is produced in Spain with a US License number 2241. It comes in a single-dose vial with a preservative-free 400 mg/16 mL dose (25mg/mL) for Intravenous Infusion after dilution. The diluted medication must be administered only for the prescribed use. The product should be refrigerated at 2°C to 8°C (36°F to 46°F) and stored in the original carton. It is essential to avoid freezing or shaking. The package contains instructions, including dosage directives.*

This is a description of a medication called Alymsys with the active ingredient bevacizumab given through injection or intravenous infusion. It comes in a single-dose vial of 1100 mg/4 mL (25 mg/mL) and must be stored refrigerated between 2-8°C (36°F to 46°F) in the original carton to protect it from light. It cannot be frozen or shaken and contains no preservatives. Dilution in 0.9% Sodium Chloride Injection, USP is necessary before intravenous use. Dosage instructions can be found in the prescribing information. The medication is manufactured by Amneal Pharmaceuticals and the product is a property of SPAN.*

This is a description of an injectable medication packaging by Amneal Pharmaceuticals called Alymsys. It is manufactured in Spain and has a concentration of 1100 mg/4 mL (25 mg/mL). The medication comes in a single-dose vial that should be stored in the original carton in refrigeration between 2°C to 8°C (36°F to 46°F). It should not be frozen or shaken, contains no preservatives, and must be diluted with 0.9% Sodium phloride Injection, USP before Intravenous Infusion. The preservative-free 100 mg/4 mL (25 mg/mL) single-dose vial of ALYMSYS is composed of 25 mg bevacizumab, 60 mg a, a-trehalose dihydrate, 0.4 mg polysorbate 20, 1.2 mg sodium phosphate (dibasic, anhydrous), 5.8 mg sodium phosphate (monobasic, monohydrate), and water for injection, USP. Dosage should be determined by a licensed medical practitioner according to the prescribing information.*

This is a description of a medicine called evacizumab-ma y. The medicine must be stored in a cool and protected place, but should not be frozen or shaken. The dosage information is available with the prescribing information. The medicine should be diluted in 0.9% Esic! for intravenous infusion, and the unused portion should be discarded.*